AnaptysBio Cash Flow Statement
NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AnaptysBio free cash flow
In fiscal 2025, AnaptysBio generated $19.7 million of operating cash flow and spent $87,000 on capital expenditures. That left free cash flow of $19.6 million, a free-cash-flow margin of 8.4% of revenue. AnaptysBio returned $68.6 million to shareholders through share repurchases, equal to 350% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
AnaptysBio cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -13.23M | -145.23M | -163.62M | -128.72M | -57.80M | -19.93M | -97.34M | -61.66M | -30.07M | -4.26M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 20.00K | 20.00K | 652.00K | 675.00K | 619.00K | 559.00K | 514.00K | 315.00K | 183.00K | 233.00K |
| Stock-Based Compensation | 3.77M | 7.22M | 33.20M | 27.36M | 15.35M | — | — | — | 4.38M | 1.16M |
| Change in Working Capital | -85.52M | -33.73M | 6.74M | 8.89M | -6.54M | -6.65M | 16.78M | 1.90M | 333.00K | -2.77M |
| Operating Cash Flow | 19.70M | -135.34M | -120.80M | -73.59M | -45.92M | -14.16M | -69.52M | -48.51M | -19.44M | -9.03M |
| Capital Expenditures | -87.00K | -358.00K | -807.00K | -358.00K | -1.37M | -569.00K | -805.00K | -1.06M | -290.00K | -50.00K |
| Investing Cash Flow | 228.03M | 31.36M | 144.75M | -394.85M | 38.84M | 94.47M | 131.43M | -142.45M | -243.06M | -50.00K |
| Share Repurchases | -68.63M | -456.00K | -50.00M | 0 | 0 | — | — | 0 | 0 | -1.00K |
| Financing Cash Flow | -132.61M | 127.05M | -59.30M | 44.02M | 252.30M | -879.00K | -4.49M | 223.36M | 292.45M | 8.63M |
| Net Change in Cash | 115.12M | 23.08M | -35.34M | -424.42M | 245.21M | 79.44M | 57.42M | 32.41M | 29.96M | -452.00K |
| Free Cash Flow | 19.61M | -135.69M | -121.61M | -73.95M | -47.29M | -14.73M | -70.32M | -49.57M | -19.73M | -9.08M |
This table shows 10 annual periods of AnaptysBio's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ANAB's reporting calendar. What is a cash flow statement?